Cargando…

The Effects of Helicobacter Pylori Eradication on Liver Function and Metabolic Profile in Non-diabetic Non-alcoholic Steatohepatitis: A 5-year Randomized Clinical Trial

BACKGROUND: To evaluate the effects of Helicobacter pylori (HP) eradication on liver function tests (LFT) and fat content (LFC) in non-diabetic non-alcoholic steatohepatitis (NASH). METHODS: This randomized clinical trial included dyspeptic HP infected non-diabetic NASH participants. The interventio...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamali, Arsia, Karbalai, Shahrokh, Tefagh, Ghazale, Jamali, Raika, Ahmadi, Ayat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Association of Gastroerterology and Hepatology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489323/
https://www.ncbi.nlm.nih.gov/pubmed/36619724
http://dx.doi.org/10.34172/mejdd.2022.260
_version_ 1784792851987562496
author Jamali, Arsia
Karbalai, Shahrokh
Tefagh, Ghazale
Jamali, Raika
Ahmadi, Ayat
author_facet Jamali, Arsia
Karbalai, Shahrokh
Tefagh, Ghazale
Jamali, Raika
Ahmadi, Ayat
author_sort Jamali, Arsia
collection PubMed
description BACKGROUND: To evaluate the effects of Helicobacter pylori (HP) eradication on liver function tests (LFT) and fat content (LFC) in non-diabetic non-alcoholic steatohepatitis (NASH). METHODS: This randomized clinical trial included dyspeptic HP infected non-diabetic NASH participants. The intervention arm received HP eradication treatment, while the control arm did not get any HP treatment. In the meantime, the standard management of NASH was performed in both trial arms. Mean alterations in LFT were the primary outcome and the secondary outcomes included the mean changes in LFC and serum metabolic profile. The trial follow-up period was 5 years. RESULTS: 40 participants (female: 20), with a mean age of 41.58 (±12.31) years, were enrolled in the study. The HP eradication arm included 20 participants (female: 11) with a mean age of 40.25 (±10.59) years, and the control arm consisted of 20 individuals (female: 9) with a mean age of 42.90 (±13.97) years. The tests of within-subjects effects showed a significant decrease in mean serum alanine aminotransferase (ALT; P=0.007), triglyceride (TG; P=0.04), cholesterol (P=0.004), and fasting blood sugar (FBS; P<0.001), and an increase in high-density lipoprotein (HDL; P=0.04) in both research groups during the study period. The tests of between-subjects effects demonstrated a more significant decrement of FBS in HP eradicated patients than the controls (P=0.02). The reduction in waist circumference, aspartate aminotransferase (AST), ALT, alkaline phosphatase, triglyceride, cholesterol, low-density lipoprotein, insulin, and LFC were more prominent in the intervention group than the controls; however, these differences were not statistically significant. CONCLUSION: Adding HP eradication treatment to standard NASH treatment showed more therapeutic effect thanthe standard NASH treatment protocol alone regarding the decrement of FBS in participants with dyspeptic non-diabetic NASH. Considering the non-statistically significant improvement in other metabolic indices and LFT in this trial, further studies are recommended.
format Online
Article
Text
id pubmed-9489323
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Iranian Association of Gastroerterology and Hepatology
record_format MEDLINE/PubMed
spelling pubmed-94893232023-01-05 The Effects of Helicobacter Pylori Eradication on Liver Function and Metabolic Profile in Non-diabetic Non-alcoholic Steatohepatitis: A 5-year Randomized Clinical Trial Jamali, Arsia Karbalai, Shahrokh Tefagh, Ghazale Jamali, Raika Ahmadi, Ayat Middle East J Dig Dis Original Article BACKGROUND: To evaluate the effects of Helicobacter pylori (HP) eradication on liver function tests (LFT) and fat content (LFC) in non-diabetic non-alcoholic steatohepatitis (NASH). METHODS: This randomized clinical trial included dyspeptic HP infected non-diabetic NASH participants. The intervention arm received HP eradication treatment, while the control arm did not get any HP treatment. In the meantime, the standard management of NASH was performed in both trial arms. Mean alterations in LFT were the primary outcome and the secondary outcomes included the mean changes in LFC and serum metabolic profile. The trial follow-up period was 5 years. RESULTS: 40 participants (female: 20), with a mean age of 41.58 (±12.31) years, were enrolled in the study. The HP eradication arm included 20 participants (female: 11) with a mean age of 40.25 (±10.59) years, and the control arm consisted of 20 individuals (female: 9) with a mean age of 42.90 (±13.97) years. The tests of within-subjects effects showed a significant decrease in mean serum alanine aminotransferase (ALT; P=0.007), triglyceride (TG; P=0.04), cholesterol (P=0.004), and fasting blood sugar (FBS; P<0.001), and an increase in high-density lipoprotein (HDL; P=0.04) in both research groups during the study period. The tests of between-subjects effects demonstrated a more significant decrement of FBS in HP eradicated patients than the controls (P=0.02). The reduction in waist circumference, aspartate aminotransferase (AST), ALT, alkaline phosphatase, triglyceride, cholesterol, low-density lipoprotein, insulin, and LFC were more prominent in the intervention group than the controls; however, these differences were not statistically significant. CONCLUSION: Adding HP eradication treatment to standard NASH treatment showed more therapeutic effect thanthe standard NASH treatment protocol alone regarding the decrement of FBS in participants with dyspeptic non-diabetic NASH. Considering the non-statistically significant improvement in other metabolic indices and LFT in this trial, further studies are recommended. Iranian Association of Gastroerterology and Hepatology 2022-01 2022-01-30 /pmc/articles/PMC9489323/ /pubmed/36619724 http://dx.doi.org/10.34172/mejdd.2022.260 Text en © 2022 Middle East Journal of Digestive Diseases https://creativecommons.org/licenses/by-nc/4.0/This work is published by Middle East Journal of Digestive Diseases as an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Original Article
Jamali, Arsia
Karbalai, Shahrokh
Tefagh, Ghazale
Jamali, Raika
Ahmadi, Ayat
The Effects of Helicobacter Pylori Eradication on Liver Function and Metabolic Profile in Non-diabetic Non-alcoholic Steatohepatitis: A 5-year Randomized Clinical Trial
title The Effects of Helicobacter Pylori Eradication on Liver Function and Metabolic Profile in Non-diabetic Non-alcoholic Steatohepatitis: A 5-year Randomized Clinical Trial
title_full The Effects of Helicobacter Pylori Eradication on Liver Function and Metabolic Profile in Non-diabetic Non-alcoholic Steatohepatitis: A 5-year Randomized Clinical Trial
title_fullStr The Effects of Helicobacter Pylori Eradication on Liver Function and Metabolic Profile in Non-diabetic Non-alcoholic Steatohepatitis: A 5-year Randomized Clinical Trial
title_full_unstemmed The Effects of Helicobacter Pylori Eradication on Liver Function and Metabolic Profile in Non-diabetic Non-alcoholic Steatohepatitis: A 5-year Randomized Clinical Trial
title_short The Effects of Helicobacter Pylori Eradication on Liver Function and Metabolic Profile in Non-diabetic Non-alcoholic Steatohepatitis: A 5-year Randomized Clinical Trial
title_sort effects of helicobacter pylori eradication on liver function and metabolic profile in non-diabetic non-alcoholic steatohepatitis: a 5-year randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489323/
https://www.ncbi.nlm.nih.gov/pubmed/36619724
http://dx.doi.org/10.34172/mejdd.2022.260
work_keys_str_mv AT jamaliarsia theeffectsofhelicobacterpylorieradicationonliverfunctionandmetabolicprofileinnondiabeticnonalcoholicsteatohepatitisa5yearrandomizedclinicaltrial
AT karbalaishahrokh theeffectsofhelicobacterpylorieradicationonliverfunctionandmetabolicprofileinnondiabeticnonalcoholicsteatohepatitisa5yearrandomizedclinicaltrial
AT tefaghghazale theeffectsofhelicobacterpylorieradicationonliverfunctionandmetabolicprofileinnondiabeticnonalcoholicsteatohepatitisa5yearrandomizedclinicaltrial
AT jamaliraika theeffectsofhelicobacterpylorieradicationonliverfunctionandmetabolicprofileinnondiabeticnonalcoholicsteatohepatitisa5yearrandomizedclinicaltrial
AT ahmadiayat theeffectsofhelicobacterpylorieradicationonliverfunctionandmetabolicprofileinnondiabeticnonalcoholicsteatohepatitisa5yearrandomizedclinicaltrial
AT jamaliarsia effectsofhelicobacterpylorieradicationonliverfunctionandmetabolicprofileinnondiabeticnonalcoholicsteatohepatitisa5yearrandomizedclinicaltrial
AT karbalaishahrokh effectsofhelicobacterpylorieradicationonliverfunctionandmetabolicprofileinnondiabeticnonalcoholicsteatohepatitisa5yearrandomizedclinicaltrial
AT tefaghghazale effectsofhelicobacterpylorieradicationonliverfunctionandmetabolicprofileinnondiabeticnonalcoholicsteatohepatitisa5yearrandomizedclinicaltrial
AT jamaliraika effectsofhelicobacterpylorieradicationonliverfunctionandmetabolicprofileinnondiabeticnonalcoholicsteatohepatitisa5yearrandomizedclinicaltrial
AT ahmadiayat effectsofhelicobacterpylorieradicationonliverfunctionandmetabolicprofileinnondiabeticnonalcoholicsteatohepatitisa5yearrandomizedclinicaltrial